Nephron Research downgraded Quanterix (QTRX) to Hold from Buy with an $8 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Completes Acquisition of Akoya Biosciences
- Quanterix Revises Deadlines for Stockholder Proposals
- Quanterix HD-X Simoa gets Class 1 Medical Device registration in South Korea
- Quanterix: Strategic Growth Potential Amid Alzheimer’s Diagnostics and Akoya Merger
- Kent Lake condemns Quanterix’s failure to schedule its 2025 Annual Meeting